drugset / Trial / NCT03952299

Oxybutynin for Post-surgical Bladder Pain and Urgency

NCT03952299

Phase 3 Recruiting 100 enrolled University of California, Davis
RandomizedParallel-groupOpen-labelTreatment

Summary

Bladder pain and urgency are common after bladder surgery. The objective is to determine if transdermal administration is superior to oral administration in alleviating pain and urgency.

Timeline

Start
2021-09-01
Primary completion
2026-12-31
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Oxybutynin Small molecule 3.9 mg Intravenous
Subject Oxybutynin Small molecule 5 mg Intravenous

Indications